

ORIGINAL

#33

PTO/SB/64/PCT (10-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY UNDER 37 CFR 1.137(b)	Docket Number (Optional) Le A 32 701
---	---

First named inventor: **Elmar Reinhold Burchardt**

International (PCT) Application No.: **PCT/EP99/03392**

U.S. Application No.: **09/701,313**
(if known)

Filed: **17 May 1999**

Title: **Monoclonal Antibody and Assay for Detecting PIINP**

Attention: PCT Legal Staff
Box PCT
Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8
The undersigned hereby certifies that this paper and any papers referred
to as attached is/are being deposited with the United States Postal
Service, with sufficient postage, as first class mail in an envelope
addressed to the Assistant Commissioner for Patents, Washington, D.C.
20231 on this 27th day of November, 2002
Susan M. Pellegrino
Signature of Person Certifying

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.494(b) or (c) or 1.495(b) or (c) as applicable. The date of abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.494(g) or 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee--required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional.

1. Petition fee

☐ Small entity - fee \$ _____ (37 CFR 1.17(m)). Applicant claims small entity status.
See 37 CFR 1.27.

☒ Other than small entity - fee \$ 1,280.00 (37 CFR 1.17(m)) The Commissioner is hereby authorized to charge the fee under 37 CFR 1.17(m) to Deposit Account 13-3372. A duplicate of this sheet is attached.

2. Proper reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s) in the form of **Sequence Listing in Computer Readable Format in response to** (identify type of reply): **the Notification of a Defective Response mailed to Applicants on 04/03/2002**

- ☐ has been filed previously on _____
☐ is enclosed herewith.

***is being submitted under separate cover to the U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202. A copy of the submission is attached.**

12/06/2002 M AYPAEN 0000031 133372 09701313

01 FC:1453 1280.00 CH

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 1.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

3. Terminal disclaimer with disclaimer fee

- ☒ Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.
- ☐ A terminal disclaimer (and disclaimer fee (37 CFR 1.20(d)) of \$_____ for a small entity or \$_____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PTO/SB/63).

4. Statement. The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

11/27/2002

Date

Telephone
Number: (203) 812-6450

Susan M. Pellegrino
Signature

Susan M. Pellegrino, Reg. No. 48,972

Typed or printed name

BAYER CORPORATION
400 Morgan Lane Address
West Haven, CT 06516

Enclosures: ☐ Response

☒ Fee Payment


☐ Terminal Disclaimer Form

☒ Itemized Return Receipt Postcard.

The Commissioner is hereby authorized to charge the fee under 37 CFR 1.17(m) to Deposit Account 13-3372. A duplicate of this sheet is attached.

OIPF

SK



CRF Problem Report

The Scientific and Technical Information Center (STIC) experienced a problem when processing the following computer readable form (CRF):

Application Serial Number: 09/701,313 A
Filing Date: 11/28/2000
Date Processed by STIC: 3/13/2002

STIC Contact: Mark Spencer, 703-308-4212

Nature of Problem:

The CRF (was):

- ☒ (circle one) Damaged or Unreadable (for Unreadable, see attached)
☐ Blank (no files on CRF) (see attached)
☐ Empty file (filename present, but no bytes in file) (see attached)
☐ Virus-infected. Virus name: _____ The STIC will not process the CRF.
☐ Not saved in ASCII text
☐ Sequence Listing was embedded in the file. According to Sequence Rules, submitted file should **only** be the Sequence Listing.
☐ Did not contain a Sequence Listing. (see attached sample)
☐ Other: _____

PLEASE USE THE CHECKER VERSION 3.1 PROGRAM TO REDUCE ERRORS.

SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/ebc/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service , or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

SEQUENCE LISTING

<110> Burchardt, Elmar R.
Kroll, Werner
Gehrmann, Mathias
Schroder, Werner

<120> Monoclonal Antibody and Assay for Detecting PIIINP

<130> Le A 32 701

<140> US 09/701,313

<141> 1999-05-17

<150> PCT/EP99/03392

<151> 1999-05-17

<160> 13

<170> PatentIn version 3.1

<210> 1

<211> 519

<212> DNA

<213> Primer

<400> 1
atgatgagct ttgtgcaaaa ggggagctgg ctacttctcg ctctgcttca tccactatt 60
attttggcac aacaggaagc tgttgaagga ggatgttccc atcttggtca gtcctatgcg 120
gatagagatg tctggaagcc agaaccatgc caaatatgtg tctgtgactc aggatccggt 180
ctctgcatg acataatatg tgacgatcaa gaattagact gcccacccc agaaattcca 240
tttggagaat gttgtgcagt ttgccacag cctccaactg ctctactcg cctcctaata 300
ggcgaaggac ctcaaggccc caaggagat ccaggccctc ctggtattcc tgggagaaat 360
ggtgaccctg gtattccagg acaaccaggg tcccctgggt ctctggccc ccttgaatc 420
tgtgaatcat gccctactgg tcctcagaac tatttcccc agtatgattc atatgatgtc 480
aagtctggag tagcagtagg aggactcgca ggctatcct 519

<210> 2

<211> 173

<212> PRT

<213> Homo sapiens

<400> 2

Met Met Ser Phe Val Gln Lys Gly Ser Trp Leu Leu Leu Ala Leu Leu
1 5 10 15

His Pro Thr Ile Ile Leu Ala Gln Gln Glu Ala Val Glu Gly Gly Cys
20 25 30

Ser His Leu Gly Gln Ser Tyr Ala Asp Arg Asp Val Trp Lys Pro Glu
35 40 45

Pro Cys Gln Ile Cys Val Cys Asp Ser Gly Ser Val Leu Cys Asp Asp
50 55 60

Ile Ile Cys Asp Asp Gln Glu Leu Asp Cys Pro Asn Pro Glu Ile Pro
65 70 75 80

Phe Gly Glu Cys Cys Ala Val Cys Pro Gln Pro Pro Thr Ala Pro Thr
85 90 95

Arg Pro Pro Asn Gly Gln Gly Pro Gln Gly Pro Lys Gly Asp Pro Gly
100 105 110

Pro Pro Gly Ile Pro Gly Arg Asn Gly Asp Pro Gly Ile Pro Gly Gln
115 120 125

Pro Gly Ser Pro Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys
130 135 140

Pro Thr Gly Pro Gln Asn Tyr Ser Pro Gln Tyr Asp Ser Tyr Asp Val
145 150 155 160

Lys Ser Gly Val Ala Val Gly Gly Leu Ala Gly Tyr Pro
165 170

<210> 3
<211> 31
<212> DNA
<213> Primer

<400> 3
cgcggtacc aaggggagct ggctacttct c 31

<210> 4
<211> 30
<212> DNA
<213> Primer

<400> 4
cgcgctgcag tgtgactcag gatccgttct 30

<210> 5
<211> 29
<212> DNA
<213> Primer

<400> 5
cgccaagctt aggggaccct ggttgtcct 29

<210> 6
<211> 31
<212> DNA
<213> Primer

<400> 6
cgcggggtacc caggaagctg ttgaaggagg a 31

<210> 7
<211> 31
<212> DNA
<213> Primer

<400> 7
cgcgaagctt aggatagcct gcgagtcctc c 31

<210> 8
<211> 24
<212> PRT
<213> Homo sapiens

<400> 8
Met Arg Gly Ser His His His His His His Gly Ser Ala Cys Glu Leu
1 5 10 15

Gly Thr Gln Glu Ala Val Glu Gly
20

<210> 9
<211> 24
<212> PRT
<213> Homo sapiens

<400> 9
Met Arg Gly Ser His His His His His His Gly Ser Ala Cys Glu Leu
1 5 10 15

Gly Thr Gln Glu Ala Val Glu Gly
20

<210> 10
<211> 24
<212> PRT
<213> Homo sapiens

<400> 10
Met Arg Gly Ser His His His His His His Gly Ser Ala Cys Glu Leu
1 5 10 15

Gly Thr Gln Glu Ala Val Glu Gly
20

<210> 11
<211> 21
<212> PRT
<213> Homo sapiens

<400> 11

Gly Ser Pro Gly Pro Pro Gly Ile Cys Glu Ser Cys Pro Thr Gly Pro
1 5 10 15

Gln Asn Tyr Ser Pro
20

<210> 12

<211> 14

<212> PRT

<213> Homo sapiens

<400> 12

Ile Cys Glu Ser Cys Pro Thr Gly Gly Gln Asn Tyr Ser Pro
1 5 10

<210> 13

<211> 30

<212> DNA

<213> 'Axial Seamount' polynoid polychaete

<400> 13

cgcgaagctt gggagaatag ttctgaggac

30